中华中医药学刊

加味软肝饮治疗对肝细胞癌伴肝硬化患者疗效及生存期影响

PDF下载

田金媚 , 张丽贤 , 赵春华 , 苏淼

中华中医药学刊 | 省级项目平台 2026,44(5): 225-229

收起

中华中医药学刊 |省级项目平台 2026 , 44 (5) : 225 -229

加味软肝饮治疗对肝细胞癌伴肝硬化患者疗效及生存期影响

全屏

[Author(id=1319630545257092005, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319630545332589479, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545257092005, language=EN, stringName=Jinmei TIAN, firstName=Jinmei, middleName=null, lastName=TIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Harrison International Peace Hospital, Hengshui 053000, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319630545416475560, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545257092005, language=CN, stringName=田金媚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=哈励逊国际和平医院，河北衡水 053000, bio={"content":"

田金媚（1989-），女，河北衡水人，主治医师，硕士，研究方向：胃肠病、肝病。

"}, bioImg=null, bioContent=

田金媚（1989-），女，河北衡水人，主治医师，硕士，研究方向：胃肠病、肝病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319630545173205921, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, xref=null, ext=[AuthorCompanyExt(id=1319630545181594530, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Harrison International Peace Hospital, Hengshui 053000, Hebei, China), AuthorCompanyExt(id=1319630545185788835, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=哈励逊国际和平医院，河北衡水 053000)])]), Author(id=1319630545479390122, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319630545559081900, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545479390122, language=EN, stringName=Lixian ZHANG, firstName=Lixian, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Harrison International Peace Hospital, Hengshui 053000, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319630545617802157, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545479390122, language=CN, stringName=张丽贤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=哈励逊国际和平医院，河北衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319630545173205921, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, xref=null, ext=[AuthorCompanyExt(id=1319630545181594530, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Harrison International Peace Hospital, Hengshui 053000, Hebei, China), AuthorCompanyExt(id=1319630545185788835, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=哈励逊国际和平医院，河北衡水 053000)])]), Author(id=1319630545697493935, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319630545772991409, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545697493935, language=EN, stringName=Chunhua ZHAO, firstName=Chunhua, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Harrison International Peace Hospital, Hengshui 053000, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319630545852683186, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545697493935, language=CN, stringName=赵春华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=哈励逊国际和平医院，河北衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319630545173205921, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, xref=null, ext=[AuthorCompanyExt(id=1319630545181594530, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Harrison International Peace Hospital, Hengshui 053000, Hebei, China), AuthorCompanyExt(id=1319630545185788835, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=哈励逊国际和平医院，河北衡水 053000)])]), Author(id=1319630545919792052, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=80867609@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1319630545995289526, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545919792052, language=EN, stringName=Miao SU, firstName=Miao, middleName=null, lastName=SU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Harrison International Peace Hospital, Hengshui 053000, Hebei, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319630546066592695, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, authorId=1319630545919792052, language=CN, stringName=苏淼, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=哈励逊国际和平医院，河北衡水 053000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319630545173205921, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, xref=null, ext=[AuthorCompanyExt(id=1319630545181594530, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Harrison International Peace Hospital, Hengshui 053000, Hebei, China), AuthorCompanyExt(id=1319630545185788835, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115262629957780, companyId=1319630545173205921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=哈励逊国际和平医院，河北衡水 053000)])])]

田金媚, 张丽贤, 赵春华, 苏淼

作者信息

哈励逊国际和平医院，河北衡水 053000

通讯作者:

苏淼（1981-），男，河北衡水人，副主任医师，博士，研究方向：消化系肿瘤。E-mail：80867609@qq.com。

作者简介:

田金媚（1989-），女，河北衡水人，主治医师，硕士，研究方向：胃肠病、肝病。

Effect of Modified Ruangan Decoction (加味软肝饮) on Efficacy and Survival Period of Patients with Hepatocellular Carcinoma and Cirrhosis

Jinmei TIAN, Lixian ZHANG, Chunhua ZHAO, Miao SU

Affiliations

Harrison International Peace Hospital, Hengshui 053000, Hebei, China

出版时间: 2026-05-10 doi: 10.13193/j.issn.1673-7717.2026.05.041

文章导航

摘要

收起

目的

研究加味软肝饮加减治疗对肝细胞癌伴肝硬化患者疗效及生存期的影响。

方法

采用随机数表法将肝细胞癌伴肝硬化患者110例分为观察组和对照组，每组55例。对照组采用经导管动脉化疗栓塞术（Transcatheter arterial embolization，TACE）治疗，观察组在此基础上给予加味软肝饮加减治疗，两组均连续治疗3个月。记录并对比两组患者的临床疗效；治疗前后采用肝功能检测试剂盒检测患者的肝功能指标［谷丙转氨酶（Alanine aminotransferase，ALT）、谷草转氨酶（Aspartate aminotransferase，AST）、总胆红素（Total bilirubin，TBil）］；采用酶联免疫吸附法检测患者的肿瘤标志物［甲胎蛋白异质体3（Alpha-Fetoprotein lens culinaris agglutinin 3，AFP-L3）、烯醇化酶-1（Enolase1，ENO1）、异常凝血酶原（Abnormal prothrombin，PIVKA-Ⅱ）］水平；记录并对比治疗后患者发生的不良反应事件情况，主要包括胃肠道反应、肾功能异常、周围神经损伤、骨髓抑制。治疗后，随访1～3年，记录并对比两组患者生存率。

结果

观察组疾病控制率高于对照组（P<0.05）。ALT、AST、TBil具体浓度水平方面，治疗前两组患者对比差异无统计学意义（P>0.05），治疗后，两组患者ALT、AST、TBil具体浓度水平全部出现了下降情况（P<0.05），且相较于对照组，观察组患者这些指标更低（P<0.05）。AFP-L3、ENO1、PIVKA-Ⅱ具体浓度水平方面，治疗前两组患者对比差异无统计学意义（P>0.05），治疗后，两组患者AFP-L3、ENO1、PIVKA-Ⅱ具体浓度水平全部出现了下降情况（P<0.05），且相较于对照组，观察组患者这些指标更低（P<0.05）。治疗后观察组不良反应发生率低于对照组（P<0.05）。随访1年两组生存率差异无统计学意义（P>0.05），随访2、3年观察组生存率高于对照组（P<0.05）。

结论

加味软肝饮加减治疗对肝细胞癌伴肝硬化患者疗效良好，能改善肝功能，降低肿瘤标记物水平，延长生存期，安全性较高。

关键词

肝细胞癌 / 肝硬化 / 加味软肝饮加减

Abstract

收起

Objective

To explore the effect of Modified Ruangan Decoction (加味软肝饮) on the efficacy and survival of patients with hepatocellular carcinoma and cirrhosis.

Methods

A hundred and ten patients with hepatocellular carcinoma and cirrhosis were divided into two groups by random number table method. The control group (55 cases) was treated with transcatheter arterial chemoembolization (TACE), and the observation group (55 cases) was treated with Modified Ruangan Decoction on this basis. Two groups were treated continuously for 3 months. The clinical effects of the two groups were recorded and compared. Liver function test kit was used to detect the liver function indexes［alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) ］of the patients before and after treatment. The tumor markers of alpha-fetoprotein anisoplast 3 (AFP-L3), enolase-1 (ENO1) and abnormal prothrombin (PIVKA-Ⅱ) were detected by enzyme-linked immunosorbent assay. The adverse events were recorded and compared, including gastrointestinal reactions, renal dysfunction, peripheral nerve injury and myelosuppression. After treatment, the patients were followed up for 1 to 3 years, and the survival rate of the two groups was recorded and compared.

Results

The disease control rate of the observation group was higher than that of the control group (P<0.05) . In terms of the specific concentration levels of ALT, AST and TBil, there was no difference between the two groups before treatment (P>0.05) . After treatment, the specific concentration levels of ALT, AST and TBil of the two groups decreased (P<0.05), and compared with those in the control group, these indicators were significantly lower in the observation group (P<0.05) . In terms of the specific concentration levels of AFP-L3, ENO1 and PIVKA-Ⅱ, there was no difference between the two groups before treatment (P>0.05) . After treatment, the specific concentration levels of AFP-L3, ENO1 and PIVKA-Ⅱ in the two groups decreased (P<0.05), and compared with those in the control group, these indexes were significantly lower in the observation group (P<0.05) . After treatment, the incidence of adverse reactions in observation group was lower than that in control group (P<0.05) . There was no difference in the survival rate between the two groups during 1-year follow-up (P>0.05), and the survival rate in the 2-year and 3-year follow-up groups was higher than that in the control group (P<0.05) .

Conclusion

Modified Ruangan Decoction has good efficacy in patients with hepatocellular carcinoma and cirrhosis. It can improve liver function and reduce tumor marker levels, prolong the survival period, and is highly safe.

Key words

hepatocellular carcinoma / liver cirrhosis / Modified Ruangan Decoction (加味软肝饮)

引用本文

田金媚, 张丽贤, 赵春华, 苏淼. 加味软肝饮治疗对肝细胞癌伴肝硬化患者疗效及生存期影响. 中华中医药学刊, 2026 , 44 (5) : 225 -229 . DOI: 10.13193/j.issn.1673-7717.2026.05.041

Jinmei TIAN, Lixian ZHANG, Chunhua ZHAO, Miao SU. Effect of Modified Ruangan Decoction (加味软肝饮) on Efficacy and Survival Period of Patients with Hepatocellular Carcinoma and Cirrhosis[J]. Chinese Archives of Traditional Chinese Medicine, 2026 , 44 (5) : 225 -229 . DOI: 10.13193/j.issn.1673-7717.2026.05.041

基金

收起

河北省医学科学研究计划项目(20232171)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

［1］

Bureau of Medical Administration, National Health Commission of the People’s Republic of China．原发性肝癌诊疗指南 (2024年版) ［J］.中国实用外科杂志, 2024, 44 (4) : 361-386.

［2］

高飞，张国梁．基于网络药理学及细胞实验验证软肝饮治疗肝癌的可能［J］．辽宁中医杂志，2023，50（6）：8-14，后插1-后插3.

［3］

蒋式骊，范海纳，刘平，等．肝硬化并发肝癌的中西医结合诊治现状与评述［J］．上海中医药杂志，2023，57（8）：21-26.

［4］

SUN B, CHEN L, LEI Y, et al. Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma［J］. Br J Radiol, 2024, 97 (1159) : 1320-1327.

［5］

ZHANG X P, WANG K, WANG M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis［J］. Oncotarget, 2017, 8 (17) : 29416-29427.

［6］

袁维，孙克伟，陈斌，等．鳖龙软肝汤抗肝纤维化-肝癌“多成分-多靶点”的网络药理学研究［J］.中西医结合肝病杂志，2022，32（4）：341-346.

［7］

齐婧姝，王宇，刘成海．活血化瘀法在肝硬化中医药治疗中的实践应用与发展［J］．上海中医药杂志，2023，57（8）：27-32.

［8］

胡景春，胡高涛．加味软肝饮辅助治疗气虚血瘀型慢性乙型肝炎患者的临床疗效及对肝纤维化指标的影响［J］．临床合理用药杂志，2021，14（36）：105-107.

［9］

孙连博，马静．加味软肝饮对气虚血瘀型慢性乙型肝炎患者免疫功能的影响及疗效分析［J］．四川中医，2020，38（1）：108-111.

［10］

《中华肝脏病杂志》编辑委员会，中华医学会肝病学分会肝癌学组．肝细胞癌癌前病变的诊断和治疗多学科专家共识（2020版）［J］．临床肝胆病杂志，2020，36（3）：514-518.

［11］

中华医学会肝病学分会．肝硬化诊治指南［J］.中华肝脏病杂志，2019，27（11）：846-865.

［12］

吴勉华，石岩.中医内科学［M］. 5版．北京：中国中医药出版社，2021：252.

［13］

LLOVET J M, LENCIONI R. mRECIST for HCC: Performance and novel refinements［J］. J Hepatol, 2020, 72 (2) : 288-306.

［14］

FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］. Actas Dermosifiliogr, 2021, 112 (1) : 90-92.

［15］

SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71 (3) : 209-249.

［16］

韩家鑫，宓余强，徐亮．肝细胞癌早期筛查和诊断的研究进展［J］．临床肝胆病杂志，2023，39（6）：1468-1475.

［17］

范芯铷，刘铭佳，王庆，等．原发性肝癌的发病机制及治疗进展［J］．肝脏，2023，28（4）：391-392.

［18］

杜蔚然，郭成祥，白雪莉，等．经导管肝动脉栓塞化疗联合系统性药物治疗肝细胞癌的研究进展［J］.中华肝胆外科杂志，2023，29（12）：949-955.

［19］

陈钰，陈斌斌，赵静，等．MRI联合血清AFP-L3和VEGF水平预测TACE术治疗的原发性肝癌患者预后的价值［J］．实用肝脏病杂志，2023，26（4）：556-559.

［20］

张中华，刘扬，占玲．理气活血中药对原发性肝癌介入术后增效减毒的结局观察及作用机制探究［J］.中华中医药学刊，2023，41（2）：163-166.

［21］

丁帅，杨永俊，李帅，等．柔肝化纤颗粒联合恩替卡韦对乙肝肝硬化腹水患者肝纤维化、凝血功能和氧化应激的影响［J］．广州中医药大学学报，2023，40（6）：1369-1376.

［22］

刘鹏，陈青山，杨建波．柴胡疏肝散加减联合射频消融治疗肝癌疗效研究［J］．陕西中医，2023，44（7）：892-896.

［23］

张璐莹，高明权，苏权中，等．蛋白质组学技术揭示黄当归醇作用于肝癌细胞中的靶标蛋白［J］．沈阳药科大学学报，2021，38（7）：691-698.

［24］

黄祎，夏莉，雷青松，等．柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究［J］．陆军军医大学学报，2022，44（14）：1410-1420.

［25］

方崇锴，刘思琳，郑昊，等．莪术醇通过PTEN/PI3K/AKT通路调控肝癌细胞自噬和上皮间质转化的机制［J］.中华中医药杂志，2023，38（5）：2450-2455.

［26］

杨楠，冯苗苗，岂铭伟，等．柴胡皂苷D对人三阴乳腺癌细胞MDA-MB-231增殖的影响［J］.中国老年学杂志，2022，42（13）：3277-3279.

［27］

郭双岩，梁旗，吕洁丽，等.中药当归的药理作用及机制研究进展［J］．新乡医学院学报，2023，40（7）：678-685.

［28］

李泽宇，郝二伟，杜正彩，等．桂郁金研究进展及基于质量标志物的保肝、抗肿瘤机制分析［J］.中国中药杂志，2022，47（7）：1739-1753.

［29］

张恺，赵庆华，杨静，等．扶正化瘀方联合TACE治疗肝细胞癌疗效及对患者血清PIV-KA-Ⅱ、ENO1及AFP-L3水平的影响［J］.中国药师，2021，24（12）：2212-2216.

2026年第44卷第5期

PDF下载

104

引用本文

BibTeX

文章信息

doi: 10.13193/j.issn.1673-7717.2026.05.041

首发时间：2026-10-14
出版时间：2026-05-10

补充材料

相关文章

文章信息

作者

出版历史

基金

河北省医学科学研究计划项目(20232171)

作者信息

哈励逊国际和平医院，河北衡水 053000

通讯作者:

苏淼（1981-），男，河北衡水人，副主任医师，博士，研究方向：消化系肿瘤。E-mail：80867609@qq.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2026.05.041

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT